Transaction #29072 · Form 4 · 0001104659-26-113342
IOVANCE BIOTHERAPEUTICS, INC. · Stock award · Performance Stock Units
IOVANCE BIOTHERAPEUTICS, INC. · Transacted September 30, 2026 · Filed October 2, 2026
What does this filing report?
An SEC Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. records a stock award involving Performance Stock Units on September 30, 2026. The reported quantity was 135,000. The filing date is October 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001425205
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 135,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 135,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 2, 2026, 5:01 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Berkowitz Noah ↗
Chief Medical Officer
CIK 0001369900
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common stock
- Underlying quantity
- 135,000
- Conversion / exercise price
- Not reported
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
- F2
- Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F3
- Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.
- F4
- Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones.
- F5
- Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.